TIMESPAN H2020 launches ART-CARMA to manage chronic cardiometabolic disease

TIMESPAN, a consortium of 17 institutions from 14 countries has launched the ART-CARMA project, to study the management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients. Using EmbracePlus, the project aims to understand the risks of cardiometabolic illnesses such as cardiovascular disease and obesity for adults with ADHD, and how their future health can be best improved through medication.

TIMESPAN focuses on bridging the gap between mental health and cardiometabolic care. Research shows a strong link between adult ADHD and other conditions including obesity, type 2 diabetes, and cardiovascular disease. Many national guidelines on cardiometabolic disease stress the importance of addressing concurrent psychiatric disorders, yet there is a knowledge gap regarding ADHD. TIMESPAN aims to bridge this gap, making improvements to risk stratification and treatment for ADHD patients living with cardiometabolic disease.